A5081040737- Lipoproteins and Cardiovascular Health
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Cancer, Lipids, and Metabolism
- Health Systems, Economic Evaluations, Quality of Life
- Lipid metabolism and disorders
- Pharmaceutical Economics and Policy
- Autoimmune Bullous Skin Diseases
- Liver Disease Diagnosis and Treatment
- Urticaria and Related Conditions
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Diabetes Treatment and Management
- Cardiac Health and Mental Health
- Fatty Acid Research and Health
- Dermatology and Skin Diseases
- Cancer, Hypoxia, and Metabolism
- Diet, Metabolism, and Disease
- Diet and metabolism studies
- Herpesvirus Infections and Treatments
- Chronic Lymphocytic Leukemia Research
- Metabolism, Diabetes, and Cancer
- Antiplatelet Therapy and Cardiovascular Diseases
- Genetic factors in colorectal cancer
- Hair Growth and Disorders
- Atherosclerosis and Cardiovascular Diseases
- Computational Drug Discovery Methods
Florida Atlantic University
2016-2025
Tel Aviv University
2006-2025
Sheba Medical Center
2010-2025
UCLouvain
2024
University of Virginia Health System
2024
Baylor University Medical Center
2024
Medical University of South Carolina
2024
Senju Pharmaceutical (United States)
2021-2024
Heart Foundation
2024
Merck & Co., Inc., Rahway, NJ, USA (United States)
2024
Lipoprotein(a) levels are genetically determined and, when elevated, a risk factor for cardiovascular disease and aortic stenosis. There no approved pharmacologic therapies to lower lipoprotein(a) levels.We conducted randomized, double-blind, placebo-controlled, dose-ranging trial involving 286 patients with established screening of at least 60 mg per deciliter (150 nmol liter). Patients received the hepatocyte-directed antisense oligonucleotide AKCEA-APO(a)-LRx, referred here as APO(a)-LRx...
Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no approved treatment. Resmetirom an oral, liver-directed, thyroid hormone receptor beta–selective agonist in development for the treatment of NASH fibrosis. Download PDF Research Summary. We are conducting ongoing phase 3 trial involving adults biopsy-confirmed and fibrosis stage F1B, F2, or F3 (stages range from F0 [no fibrosis] to F4 [cirrhosis]). Patients were randomly assigned 1:1:1 ratio receive once-daily...
<h3>Importance</h3> Additional treatment options are needed for patients who do not achieve sufficient reduction in low-density lipoprotein cholesterol (LDL-C) level with available lipid-lowering therapies. <h3>Objective</h3> To assess the efficacy of bempedoic acid vs placebo at high cardiovascular risk receiving maximally tolerated therapy. <h3>Design, Setting, and Participants</h3> Phase 3, randomized, double-blind, placebo-controlled clinical trial conducted 91 sites North America Europe...
Lipoprotein(a) is a presumed risk factor for atherosclerotic cardiovascular disease. Olpasiran small interfering RNA that reduces lipoprotein(a) synthesis in the liver.
Patients with refractory hypercholesterolemia, who have high low-density lipoprotein (LDL) cholesterol levels despite treatment lipid-lowering therapies at maximum tolerated doses, an increased risk of atherosclerosis. In such patients, the efficacy and safety subcutaneous intravenous evinacumab, a fully human monoclonal antibody against angiopoietin-like 3, are not known.In this double-blind, placebo-controlled, phase 2 trial, we enrolled patients or without heterozygous familial...
Loss-of-function mutations in ANGPTL3 are associated with beneficial effects on lipid and glucose metabolism reduced risk of coronary artery disease. Vupanorsen (AKCEA-ANGPTL3-L Rx ) is an N-acetyl galactosamine-conjugated antisense oligonucleotide targeted to the liver that selectively inhibits angiopoietin-like 3 (ANGPTL3) protein synthesis.This was a double-blind, placebo-controlled, dose-ranging, Phase 2 study. Patients (N =105) fasting triglycerides >150 mg/dL (>1.7 mmol/L), type...
Background— Cardiovascular disease burden and treatment patterns among patients with familial hypercholesterolemia (FH) in the United States remain poorly described. In 2013, FH Foundation launched Cascade Screening for Awareness Detection (CASCADE) of Registry to address this knowledge gap. Methods Results— We conducted a cross-sectional analysis 1295 adults heterozygous enrolled CASCADE-FH from 11 US lipid clinics. Median age at initiation lipid-lowering therapy was 39 years, median...
Abstract Aims Hypertriglyceridaemia is associated with increased risk of cardiovascular events. This clinical trial evaluated olezarsen, an N-acetyl-galactosamine-conjugated antisense oligonucleotide targeted to hepatic APOC3 mRNA inhibit apolipoprotein C-III (apoC-III) production, in lowering triglyceride levels patients at high for or established disease. Methods and results A randomized, double-blind, placebo-controlled, dose-ranging study was conducted 114 fasting serum triglycerides...
Guidelines for patients with atherosclerotic cardiovascular disease (ASCVD) recommend intensive statin therapy and adding nonstatin if low-density lipoprotein cholesterol (LDL-C) levels are 70 mg/dL or more. Compliance guidelines is often low.
BackgroundObesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, causes considerable weight loss, but data are lacking respect to its effects on cardiovascular outcomes.MethodsIn this international, double-blind, randomized, placebo-controlled trial, we randomly assigned, in 1:1 ratio, 731 patients failure, an fraction at least 50%, body-mass index...
Severe hypertriglyceridemia (sHTG) is an established risk factor for acute pancreatitis. Current therapeutic approaches sHTG are often insufficient to reduce triglycerides and prevent This phase 2 trial ( NCT03452228 ) evaluated evinacumab (angiopoietin-like 3 inhibitor) in three cohorts of patients with sHTG: cohort 1, familial chylomicronemia syndrome bi-allelic loss-of-function lipoprotein lipase (LPL) pathway mutations (n = 17); 2, multifactorial heterozygous LPL 15); 3, without 19)....
The coronavirus disease 2019 (COVID-19) pandemic has consumed our healthcare system, with immediate resource focus on the management of high numbers critically ill patients. Those that fare poorly COVID-19 infection more commonly have cardiovascular (CVD), hypertension and diabetes. There are also several other conditions raise concern for welfare patients at risk CVD during this pandemic. Traditional ambulatory care is disrupted many delaying or deferring necessary care, including...
Atherosclerotic cardiovascular disease remains a major cause of death and disability, especially for high-risk familial hypercholesterolemia individuals. PCSK9i (proprotein convertase subtilisin kexin type 9 inhibitors) reduce low-density lipoprotein cholesterol levels event rates. However, prescriptions are rejected at high rates by payers, use is often delayed or eventually abandoned as treatment option. We tested the hypothesis that acute coronary syndromes, interventions, stroke, cardiac...
Bruton tyrosine kinase (BTK) inhibition targets B-cell and other non-T-cell immune cells implicated in the pathophysiology of pemphigus, an autoimmune disease driven by anti-desmoglein autoantibodies. Rilzabrutinib is a new reversible, covalent BTK inhibitor demonstrating preclinical efficacy as monotherapy canine pemphigus foliaceus.To evaluate safety oral rilzabrutinib patients with vulgaris multicentre, proof-of-concept, phase II trial.Patients Pemphigus Disease Area Index severity scores...
BACKGROUND: Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder characterized by severely elevated low-density lipoprotein cholesterol (LDL-C) levels due to profoundly defective LDL receptor (LDLR) function. Given that LDL-C starts in utero, atherosclerosis often presents during childhood or adolescence, creating largely unmet need for aggressive LDLR-independent lipid-lowering therapies young patients with HoFH. Here we present the first evaluation of efficacy and...
Background Homozygous familial hypercholesterolemia (HoFH) is a rare, treatment‐resistant disorder characterized by early‐onset atherosclerotic and aortic valvular cardiovascular disease if left untreated. Contemporary information on HoFH in the United States lacking, extent of underdiagnosis undertreatment uncertain. Methods Results Data were analyzed from 67 children adults with clinically diagnosed CASCADE (Cascade Screening for Awareness Detection) FH Registry. Genetic diagnosis was...
Olpasiran, a small interfering RNA (siRNA), blocks lipoprotein(a) (Lp(a)) production by preventing translation of apolipoprotein(a) mRNA. In phase 2, higher doses olpasiran every 12 weeks (Q12W) reduced circulating Lp(a) >95%.